Maxim Group analyst Anthony Vendetti maintained a Buy rating on BioPharmX Corp (BPMX) today and set a price target of $0.40. The company’s shares opened today at $0.13.
Vendetti wrote:
“On March 14, 2019, BPMX reported a F4Q19 (Jan) GAAP loss per share inline with our estimate.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 7.5% and a 53.2% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Ra Medical Systems Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for BioPharmX Corp.
See today’s analyst top recommended stocks >>
Based on BioPharmX Corp’s latest earnings release for the quarter ending January 31, the company reported a quarterly GAAP net loss of $4.06 million. In comparison, last year the company had a GAAP net loss of $3.79 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioPharmX Corp. engages in the provision of healthcare products through platform technologies for pharmaceutical, over-the-counter, and supplement applications in dermatology. Its platforms include Topical Gel, Injectable, and Encapsulation.
